TWD 62.8
(7.72%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 24.58 Million TWD | -13.14% |
2022 | 28.3 Million TWD | -15.34% |
2021 | 33.43 Million TWD | 2.8% |
2020 | 32.52 Million TWD | 19.96% |
2019 | 27.11 Million TWD | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q2 | 27.48 Million TWD | -13.9% |
2024 Q1 | 31.91 Million TWD | 29.81% |
2023 Q3 | 25.76 Million TWD | -42.25% |
2023 Q2 | 44.6 Million TWD | 104.69% |
2023 Q4 | 24.58 Million TWD | -4.56% |
2023 Q1 | 21.79 Million TWD | -23.02% |
2022 Q4 | 28.3 Million TWD | 0.0% |
2022 FY | 28.3 Million TWD | -15.34% |
2021 FY | 33.43 Million TWD | 2.8% |
2020 FY | 32.52 Million TWD | 19.96% |
2019 FY | 27.11 Million TWD | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Apex Biotechnology Corp. | 500.07 Million TWD | 95.083% |
Sinphar Pharmaceutical Co.,Ltd. | 2.85 Billion TWD | 99.138% |
Panion & Bf Biotech Inc. | 1.32 Billion TWD | 98.143% |
Chunghwa Chemical Synthesis & Biotech Co., Ltd. | 1.82 Billion TWD | 98.65% |
GenMont Biotech Incorporation | 204.05 Million TWD | 87.951% |
Abnova (Taiwan) Corporation | 69.42 Million TWD | 64.584% |
Adimmune Corporation | 3.7 Billion TWD | 99.337% |
Tanvex BioPharma, Inc. | 1.94 Billion TWD | 98.734% |
Polaris Group | 1.46 Billion TWD | 98.321% |
UnicoCell Biomed Co., Ltd. | 89.48 Million TWD | 72.525% |
PELL Bio-Med Technology Co. Ltd. | 236.76 Million TWD | 89.615% |